Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPRS1 | P07814 | 6/20 | 0.67 |
| ▸ | DHODH | Q02127 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15919554 | 0.85 | EPRS1 (0.60) | EPRS1DHODHHIF1AHSD17B10ALDH1A1 | |
| SCHEMBL15919736 | 0.84 | EPRS1 (0.47) | EPRS1DHODHTP53CYP1A2CYP2C19 | |
| SCHEMBL117388 | 0.80 | EPRS1 (1.00) | EPRS1DHODHHIF1AHSD17B10ALDH1A1 | |
| SCHEMBL15905102 | 0.80 | EPRS1 (0.64) | EPRS1DHODHALDH1A1GAA | |
| SCHEMBL117430 | 0.79 | EPRS1 (0.79) | EPRS1DHODHHIF1AHSD17B10ALDH1A1 | |
| SCHEMBL15919570 | 0.79 | MAPT (0.44) | EPRS1ALDH1A1GAAMAPT | |
| SCHEMBL29788463 | 0.78 | DHODH (0.80) | EPRS1DHODHTP53 | |
| SCHEMBL116022 | 0.78 | DHODH (0.80) | EPRS1DHODHTP53 | |
| SCHEMBL31590457 | 0.76 | PTGES (0.68) | EPRS1DHODHHIF1AHSD17B10ALDH1A1 | |
| SCHEMBL5792900 | 0.75 | DHODH (0.78) | EPRS1DHODHHIF1AHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| WO-2014117090-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | EPRS1 1402/4885DHODH 554/4885TP53 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.